SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Academic Article uri icon

Overview

abstract

  • The Sox4 transcription factor mediates early B-cell differentiation. Compared with normal pre-B cells, SOX4 promoter regions in Ph(+) ALL cells are significantly hypomethylated. Loss and gain-of-function experiments identified Sox4 as a critical activator of PI3K/AKT and MAPK signaling in ALL cells. ChIP experiments confirmed that SOX4 binds to and transcriptionally activates promoters of multiple components within the PI3K/AKT and MAPK signaling pathways. Cre-mediated deletion of Sox4 had little effect on normal pre-B cells but compromised proliferation and viability of leukemia cells, which was rescued by BCL2L1 and constitutively active AKT and p110 PI3K. Consistent with these findings, high levels of SOX4 expression in ALL cells at the time of diagnosis predicted poor outcome in a pediatric clinical trial (COG P9906). Collectively, these studies identify SOX4 as a central mediator of oncogenic PI3K/AKT and MAPK signaling in ALL.

publication date

  • November 14, 2012

Research

keywords

  • Gene Expression Regulation, Leukemic
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • SOXC Transcription Factors
  • Signal Transduction

Identity

PubMed Central ID

  • PMC3538327

Scopus Document Identifier

  • 84872079829

Digital Object Identifier (DOI)

  • 10.1182/blood-2012-05-428938

PubMed ID

  • 23152540

Additional Document Info

volume

  • 121

issue

  • 1